Abstract library

215 results for "diagnostic".
#74 Non-functioning pancreatic endocrine tumors: diagnostic criteria and surgical treatment
Introduction: Neuroendocrine tumors were considered rare tumors several years ago. Several reports published recently have observed increased incidence of NETs suggesting that NETs are more prevalent than previously reported. Non-functioning pancreatic endocrine tumors (NFPETs), better defined as non-hyperfunctioning, are characterized by the absence of clinical or biochemical evidence of hormone hypersecretion. From the clinical standpoint, NFPETs can be either occasionally encountered or manifest clinically similar pancreatic tumors. Since both NFPET treatment and prognosis significantly differ from that of ductal adenocarcinoma and other pancreatic malignant tumors, an accurate differential diagnosis is needed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alexander Vladimir Kochatkov
Authors:
#1516 Multimodal Endoscopic Diagnostics of Gastric Neuroendocrine Tumors
Introduction: From 1998 till 2014 in our institution we have diagnosed 72 type I gastric neuroendocrine tumors (NET) with upper gastrointestinal endoscopy.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Sergey Pirogov
Authors:
#221 Diagnostic Algorithm of Pancreatic Neuroendocrine Tumors
Introduction: Diagnostics of pNETs is associated with certain problems due to a variety of clinical features, including a rather small size of primaries and, quite often, multiple lesions.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan A Vasiliev
Authors:
#1597 The Diagnostic and Prognostic Value of Plasma CgA in Nonfunctional Pancreatic Neuroendocrine Neoplasms
Introduction: Controversies still remain on the diagnostic and prognostic value of CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors:
#2272 Enhancing Diagnostic Precision Through Combined Genomic and Histopathological Analysis of Pancreatic Neuroendocrine Tumors
Introduction: Diagnostic differentiation of uncommon pancreatic malignancies can be challenging, but is essential for accurate clinical management; genomic analysis may provide a tool for making this critical distinction.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Tamsin Robb
Authors:
#2084 A Comparison of Diagnostic and Management Pathways for Patients with Lung Neuroendocrine Tumors in ENETS Centres of Excellence vs Non-Accredited Centres in the UK: Results from the National Lung NET Pathway Project (‘LEAP’)
Introduction: The ENETS network of accredited NET Centres of Excellence (CoE) across Europe was established to standardise and improve NET management.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Stuart Ferguson
Authors:
#953 Comparison of Diagnostic Methods in the Evaluation of Pancreatic and Duodenal Gastrinomas
Introduction: Gastrinomas are neuroendocrine tumors, mainly located in the duodenum or the pancreas, that secrete gastrin and cause a clinical syndrome known as ZES.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: M.D., PhD. Peter Hyrdel
Authors:
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors:
#484 Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) is a valuable diagnostic tool for patients with neuroendocrine tumors (NET). To date, a meta-analysis about the diagnostic accuracy of this functional imaging method is lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
Authors:
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Conference:
Category: Basic
Presenting Author: Mr TAO CUI
Authors: